Validating pharmaceutical systems; good computer practice in life science manufacturing.
Ed. by John Andrews.
Taylor & Francis
2006
549 pages
$249.95
Hardcover
RS122
Andrews, an experienced engineer in pharmaceuticals, compiles 20 essays and a glossary by an international group of contributors in the pharmaceutical industry. They discuss automated systems validation and regulations for drug development, production, and distribution; and they analyze the inspection, risk assessment and management, planning, reporting, auditing, specifications, documentation, testing, and calibration of validations systems. In addition, the authors explain GCP, GLP See gateway location protocol. , and GMP GMP (guanosine monophosphate): see guanine.
..... Click the link for more information. regulatory requirements, manufacturing education systems (MES (Manufacturing Execution Software) Software that provides real time access to plant activities that include equipment, labor, orders and inventory. An MES integrates the data with enterprise resource planning (ERP) systems so that management has complete control of ), and include case studies of SCADA (System Control and Data Acquisition) systems, the LIMS system (Laboratory Information Management System), GAMP 4 (Good Automated Manufacturing Practice Good Automated Manufacturing Practice (GAMP) is a technical sub-committee of the International Society of Pharmaceutical Engineering (ISPE). The goal of the committee is to promote the understanding of the regulation and use of automated systems within the pharmaceutical ), and validation in Central and Eastern Europe The term "Central and Eastern Europe" came into wide spread use, replacing "Eastern bloc", to describe former Communist countries in Europe, after the collapse of the Iron Curtain in 1989/90.
..... Click the link for more information..
Wednesday, November 25, 2009
Drug Target Validation
DUBLIN, Ireland -- Research and Markets (http://www.researchandmarkets.com/reports/c31977) has announced the addition of Strategies for Drug Target Identification and Validation See validate.
validation - The stage in the software life-cycle at the end of the development process where software is evaluated to ensure that it complies with the requirements. to their offering.
Target-based drug discovery has become the prevailing paradigm used by pharmaceutical and biotechnology companies Top 100 Biotechnology Companies
The following is a list of the top 100 biotechnology companies ranked by revenue. The first nine companies qualify for the list of the top 50 pharmaceutical companies.
..... Click the link for more information.. This approach is appealing because it holds the promise of identifying more-efficacious compounds with fewer undesirable side effects Side effects
Effects of a proposed project on other parts of the firm.
..... Click the link for more information.. Companies have therefore invested significant resources in acquiring and developing technologies for identifying and validating new drug targets. This report explores both state-of-the-art and emerging target identification and validation technologies and methods. We consider the limitations of these technologies and their impact on drug discovery, examine relevant business models, and profile selected companies with novel target identification and validation technologies.
Business Implications
--Target-based drug discovery has become the prevailing paradigm used by pharmaceutical and biotechnology companies. This approach is appealing because it holds the promise of identifying more-efficacious compounds with fewer undesirable side effects. Companies have therefore invested significant resources in acquiring and developing technologies for identifying and validating new drug targets.
--A wide array of target identification technologies is available, including genomics, gene expression profiling Microarray technology is often used for gene expression profiling. It makes use of the sequence resources created by the genome sequencing projects and other sequencing efforts to answer the question, , and proteomics pro·te·o·mics
n.
The analysis of the expression, localization, functions, and interactions of the proteins produced by the genes of an organism.
..... Click the link for more information.. Biomarkers and metabolomic profiling are emerging tools for monitoring the biological effects of manipulating a potential drug target. Technologies such as gene knockouts This article or section is in need of attention from an expert on the subject.
Please help recruit one or [ improve this article] yourself. See the talk page for details. , RNA interference RNA interference
n.
A process in which the introduction of double-stranded RNA into a cell inhibits the expression of genes.
..... Click the link for more information. (RNAi), and protein inhibition provide researchers with a multipronged mul·ti·pronged
adj.
1. Having many prongs.
2. Involving several different directions, aspects, or elements: a multipronged attack; a multipronged tax bill. approach to validating new targets. The most successful approaches combine several technologies to provide a detailed understanding of the biological effects of altering the activity of a single target.
--Target identification and validation technologies form a critical foundation for modern drug discovery. These approaches provide a rich source of intellectual property and can be valuable competitive differentiators for companies seeking proprietary positions for drugs that act through novel mechanisms. Emerging technologies such as RNAi and metabolic met·a·bol·ic
adj.
Of, relating to, or resulting from metabolism.
Metabolic
Refers to the chemical processes of an organ or organism. profiling hold a great deal of promise for improving the efficiency and efficacy of drug target validation.
Topics Covered
--Introduction
--Drug Target Identification
--Target Validation Technologies
--Impact of New Targets on Drug Discovery
--Corporate Highlights
--Outlook
Companies mentioned in this report include:
--ActivX
--Alnylam Pharmaceuticals
--Ambion
--Amphora Discovery
--Archemix
--Atugen Biotechnology
--Cenix BioScience
--Cubist Pharmaceuticals
--CuraGen
--Deltagen
--DeveloGen
--DevGen
--Dharmacon
--EpiGenesis Pharmaceuticals
--Exelixis
--GeneData
--genOway
--Icoria
--Ingenium Pharmaceuticals
--Isis Pharmaceuticals
--Lexicon Genetics
--Metabolon
--Phenomenome Discoveries
--Quark Biotech bi·o·tech
n. Informal
Biotechnology.
biotech
Noun
short for biotechnology
Noun 1.
--Rigel
--Xenogen
--Xenon Genetics
--Zygogen
For more information visit http://www.researchandmarkets.com/reports/c31977
Source: Decision Resources
validation - The stage in the software life-cycle at the end of the development process where software is evaluated to ensure that it complies with the requirements. to their offering.
Target-based drug discovery has become the prevailing paradigm used by pharmaceutical and biotechnology companies Top 100 Biotechnology Companies
The following is a list of the top 100 biotechnology companies ranked by revenue. The first nine companies qualify for the list of the top 50 pharmaceutical companies.
..... Click the link for more information.. This approach is appealing because it holds the promise of identifying more-efficacious compounds with fewer undesirable side effects Side effects
Effects of a proposed project on other parts of the firm.
..... Click the link for more information.. Companies have therefore invested significant resources in acquiring and developing technologies for identifying and validating new drug targets. This report explores both state-of-the-art and emerging target identification and validation technologies and methods. We consider the limitations of these technologies and their impact on drug discovery, examine relevant business models, and profile selected companies with novel target identification and validation technologies.
Business Implications
--Target-based drug discovery has become the prevailing paradigm used by pharmaceutical and biotechnology companies. This approach is appealing because it holds the promise of identifying more-efficacious compounds with fewer undesirable side effects. Companies have therefore invested significant resources in acquiring and developing technologies for identifying and validating new drug targets.
--A wide array of target identification technologies is available, including genomics, gene expression profiling Microarray technology is often used for gene expression profiling. It makes use of the sequence resources created by the genome sequencing projects and other sequencing efforts to answer the question, , and proteomics pro·te·o·mics
n.
The analysis of the expression, localization, functions, and interactions of the proteins produced by the genes of an organism.
..... Click the link for more information.. Biomarkers and metabolomic profiling are emerging tools for monitoring the biological effects of manipulating a potential drug target. Technologies such as gene knockouts This article or section is in need of attention from an expert on the subject.
Please help recruit one or [ improve this article] yourself. See the talk page for details. , RNA interference RNA interference
n.
A process in which the introduction of double-stranded RNA into a cell inhibits the expression of genes.
..... Click the link for more information. (RNAi), and protein inhibition provide researchers with a multipronged mul·ti·pronged
adj.
1. Having many prongs.
2. Involving several different directions, aspects, or elements: a multipronged attack; a multipronged tax bill. approach to validating new targets. The most successful approaches combine several technologies to provide a detailed understanding of the biological effects of altering the activity of a single target.
--Target identification and validation technologies form a critical foundation for modern drug discovery. These approaches provide a rich source of intellectual property and can be valuable competitive differentiators for companies seeking proprietary positions for drugs that act through novel mechanisms. Emerging technologies such as RNAi and metabolic met·a·bol·ic
adj.
Of, relating to, or resulting from metabolism.
Metabolic
Refers to the chemical processes of an organ or organism. profiling hold a great deal of promise for improving the efficiency and efficacy of drug target validation.
Topics Covered
--Introduction
--Drug Target Identification
--Target Validation Technologies
--Impact of New Targets on Drug Discovery
--Corporate Highlights
--Outlook
Companies mentioned in this report include:
--ActivX
--Alnylam Pharmaceuticals
--Ambion
--Amphora Discovery
--Archemix
--Atugen Biotechnology
--Cenix BioScience
--Cubist Pharmaceuticals
--CuraGen
--Deltagen
--DeveloGen
--DevGen
--Dharmacon
--EpiGenesis Pharmaceuticals
--Exelixis
--GeneData
--genOway
--Icoria
--Ingenium Pharmaceuticals
--Isis Pharmaceuticals
--Lexicon Genetics
--Metabolon
--Phenomenome Discoveries
--Quark Biotech bi·o·tech
n. Informal
Biotechnology.
biotech
Noun
short for biotechnology
Noun 1.
--Rigel
--Xenogen
--Xenon Genetics
--Zygogen
For more information visit http://www.researchandmarkets.com/reports/c31977
Source: Decision Resources
principles of validation to non-actives.
ALEXANDRIA, VA--Excipient makers are debating whether to apply validation principles to their products, as the European Union European Union (EU), name given since the ratification (Nov., 1993) of the Treaty of European Union, or Maastricht Treaty, to the
European Community
..... Click the link for more information. and individual members continue to discuss extending GMPs to all excipients excipients,
n.pl all the constituents of a remedy that lack medicinal properties. See also adjuvant, auxiliary substance, and vehicle.
..... Click the link for more information., especially in light of events--mostly in the 1990s--where hundreds of patients died due to deadly ingredients in drug products.
Members of the International Pharmaceutical Excipients Council International Pharmaceutical Excipients Council is a global organization representing producers, suppliers, and end users of excipients. The body has three divisions in Europe, Japan, and the United States, each of which focuses on local regulations concerning the excipients
..... Click the link for more information. of the Americas (IPEC IPEC International Programme on the Elimination of Child Labour
IPEC International Pharmaceutical Excipients Council
IPEC International Power Electronics Conference
IPEC International Power Engineering Conference
IPEC Integrated Petroleum Environmental Consortium
..... Click the link for more information.) met in Washington Sept. 11 to discuss an internal guidance to apply some level of validation to non-actives used in drug products.
Sidney Goode, project leader for Global GMP GMP (guanosine monophosphate): see guanine. SME (1) (Small and Medium-sized Enterprise) See SMB.
(2) (Subject Matter Expert) An individual who is well-versed in the policies and procedures of a particular department or division. for Dow Chemical, Harbor Beach, MI, and chair of the IPEC GMP Committee, wrote in an email: "The final guidance, if not called validation, will employ the principles of validation focused on providing process and systems that produce consistent quality products to market."
He said, "the scope is to include equipment, processes, methodology and computer systems." The "next project will be to guide the group in working with IPEC Europe to develop guidance defining the validation needs/requirements for the excipient excipient /ex·cip·i·ent/ (ek-sip´e-int) any more or less inert substance added to a drug to give suitable consistency or form to the drug; a vehicle.
ex·cip·i·ent
n. industry."
Goode said FDA FDA
abbr.
Food and Drug Administration
FDA,
n.pr See Food and Drug Administration.
FDA,
n.pr the abbreviation for the Food and Drug Administration. is involved in these discussions and the next meeting will be in December. David Schoneker, chairman of IPEC, and director of regulatory affairs at Colorcon, West Point, PA, said the trade group hopes to issue a document by the first quarter of 2008. IPEC recently provided members with a "Phase One Guideline" on the qualification of excipients used in drugs.
At an IPEC regulatory affairs conference that week, participants learned that there are more than 8,000 non-actives used in drug products worldwide, and that the various pharmacopoeias are approaching nearly 20,000 monographs.
Janeen Skutnik, director and team leader for compendial affairs and regulatory monitoring for Pfizer's European Service center, said firms are conducting "redundant, non value-added testing, that is providing no benefits to patients."
Goode also said there is a proliferation of master files at FDA, too. He said: "If you don't have to submit a drug master file Drug Master File or DMF is a document prepared by a manufacturer in the pharmaceutical industry and submitted solely at his discretion to the Food and Drug Administration (FDA). There is no requirement by law or FDA regulation to present a DMF. on one, please don't." FDAers at the meeting said they are trying to get a grip on the proliferation of master files.
Skutnik and other speakers said most excipient makers--at least the major and reputable ones--are "self regulating" and trying to apply facets of risk-based regulation and quality systems approaches used for active ingredients and finished drug products to excipients.
Skutnik said many firms are wise to look at ICH See Intel Hub Architecture. guidance documents Q8, Q9 and Q10 concerning quality systems.
FDAers said the agency will likely embrace the IPEC guidance for regulatory purposes. But Edwin Rivera-Martinez, chief of the Manufacturing Assessment and Pre-approval Compliance Branch in the Center for Drugs Division of Manufacturing and Product Quality, said that for FDA to devise guidance of its own is "difficult because there is a wide array of products."
He was largely referring to APIs, noting "there is wide diversity of API manufacturers. It is difficult to develop guidance for a specific industry and all excipients."
And, executives at the conference noted that when it comes to non-actives, often the same plants produce the same ingredients for foods and other products. In addition, makers of the finished dosage forms are largely held responsible for the excipients and APIs, and they are supposed to make drugs following GMPs.
By Ken Reid,
European Community
..... Click the link for more information. and individual members continue to discuss extending GMPs to all excipients excipients,
n.pl all the constituents of a remedy that lack medicinal properties. See also adjuvant, auxiliary substance, and vehicle.
..... Click the link for more information., especially in light of events--mostly in the 1990s--where hundreds of patients died due to deadly ingredients in drug products.
Members of the International Pharmaceutical Excipients Council International Pharmaceutical Excipients Council is a global organization representing producers, suppliers, and end users of excipients. The body has three divisions in Europe, Japan, and the United States, each of which focuses on local regulations concerning the excipients
..... Click the link for more information. of the Americas (IPEC IPEC International Programme on the Elimination of Child Labour
IPEC International Pharmaceutical Excipients Council
IPEC International Power Electronics Conference
IPEC International Power Engineering Conference
IPEC Integrated Petroleum Environmental Consortium
..... Click the link for more information.) met in Washington Sept. 11 to discuss an internal guidance to apply some level of validation to non-actives used in drug products.
Sidney Goode, project leader for Global GMP GMP (guanosine monophosphate): see guanine. SME (1) (Small and Medium-sized Enterprise) See SMB.
(2) (Subject Matter Expert) An individual who is well-versed in the policies and procedures of a particular department or division. for Dow Chemical, Harbor Beach, MI, and chair of the IPEC GMP Committee, wrote in an email: "The final guidance, if not called validation, will employ the principles of validation focused on providing process and systems that produce consistent quality products to market."
He said, "the scope is to include equipment, processes, methodology and computer systems." The "next project will be to guide the group in working with IPEC Europe to develop guidance defining the validation needs/requirements for the excipient excipient /ex·cip·i·ent/ (ek-sip´e-int) any more or less inert substance added to a drug to give suitable consistency or form to the drug; a vehicle.
ex·cip·i·ent
n. industry."
Goode said FDA FDA
abbr.
Food and Drug Administration
FDA,
n.pr See Food and Drug Administration.
FDA,
n.pr the abbreviation for the Food and Drug Administration. is involved in these discussions and the next meeting will be in December. David Schoneker, chairman of IPEC, and director of regulatory affairs at Colorcon, West Point, PA, said the trade group hopes to issue a document by the first quarter of 2008. IPEC recently provided members with a "Phase One Guideline" on the qualification of excipients used in drugs.
At an IPEC regulatory affairs conference that week, participants learned that there are more than 8,000 non-actives used in drug products worldwide, and that the various pharmacopoeias are approaching nearly 20,000 monographs.
Janeen Skutnik, director and team leader for compendial affairs and regulatory monitoring for Pfizer's European Service center, said firms are conducting "redundant, non value-added testing, that is providing no benefits to patients."
Goode also said there is a proliferation of master files at FDA, too. He said: "If you don't have to submit a drug master file Drug Master File or DMF is a document prepared by a manufacturer in the pharmaceutical industry and submitted solely at his discretion to the Food and Drug Administration (FDA). There is no requirement by law or FDA regulation to present a DMF. on one, please don't." FDAers at the meeting said they are trying to get a grip on the proliferation of master files.
Skutnik and other speakers said most excipient makers--at least the major and reputable ones--are "self regulating" and trying to apply facets of risk-based regulation and quality systems approaches used for active ingredients and finished drug products to excipients.
Skutnik said many firms are wise to look at ICH See Intel Hub Architecture. guidance documents Q8, Q9 and Q10 concerning quality systems.
FDAers said the agency will likely embrace the IPEC guidance for regulatory purposes. But Edwin Rivera-Martinez, chief of the Manufacturing Assessment and Pre-approval Compliance Branch in the Center for Drugs Division of Manufacturing and Product Quality, said that for FDA to devise guidance of its own is "difficult because there is a wide array of products."
He was largely referring to APIs, noting "there is wide diversity of API manufacturers. It is difficult to develop guidance for a specific industry and all excipients."
And, executives at the conference noted that when it comes to non-actives, often the same plants produce the same ingredients for foods and other products. In addition, makers of the finished dosage forms are largely held responsible for the excipients and APIs, and they are supposed to make drugs following GMPs.
By Ken Reid,
How Overcoming the Challenge of Biomarker Validation Can Pay Off for Drug and Diagnostic Developers
DUBLIN, Ireland -- Research and Markets (http://www.researchandmarkets.com/reports/c86274) has announced the addition of new Decision Resources report: How Overcoming the Challenge of Biomarker Validation Can Pay Off for Drug and Diagnostic Developers to their offering.
Introduction
Validating a biomarker is a resource-intensive undertaking. Is it worth it? We say, Yes. A biomarker that wins "known validated" status is best positioned for rewards: regulatory approval, optimal reimbursement, incorporation into personalized medicine The external links in this article or section may require cleanup to comply with Wikipedia's content policies. approaches alongside companion therapeutics, partnership and promotion opportunities, and wider awareness and uptake. Companies that recently began fielding biomarker-based tests are reporting success in terms of a revenue upswing. And they have laid the groundwork for validation of tomorrow's biomarker-based tools.
Get the Answers You Need to Shape Your Strategy
In December 2007, Panacea's LC Detect for early lung cancer lung cancer, cancer that originates in the tissues of the lungs. Lung cancer is the leading cause of cancer death in the United States in both men and women. Like other cancers, lung cancer occurs after repeated insults to the genetic material of the cell. diagnosis was named one of Time Magazine's Top 10 Medical Breakthroughs of 2007. What other biomarker-based tests are changing medical practice, and how?
- Validation is a key step in maximizing the clinical and commercial success of a biomarker. What is the validation process? What companies have successfully navigated it? What resources exist to facilitate the process?
- Validated biomarkers are the basis for several marketed companion diagnostics. Which products have received approval? How are these products faring? What tests are in development?
- For companies developing biomarker-based tests, a key strategy that taps the personalized medicine paradigm is to partner with drug developers. Which biomarker companies lead the pack? Which pharmaceutical companies have become involved in personalized medicine and drug/diagnostic co-development?
Scope
- About validated biomarkers: definitions, classifications, the value and process of validation.
- Types of biomarker-based tests: home-brew, de novo [Latin, Anew.] A second time; afresh. A trial or a hearing that is ordered by an appellate court that has reviewed the record of a hearing in a lower court and sent the matter back to the original court for a new trial, as if it had not been previously heard nor decided. , in vitro in vitro /in vi·tro/ (in ve´tro) [L.] within a glass; observable in a test tube; in an artificial environment.
in vi·tro
adj.
In an artificial environment outside a living organism. diagnostic multivariate assay, therapeutic area focus (oncology is a leading area), technology focus (nucleic-acid testing, or NAT (Network Address Translation) An IETF standard that allows an organization to present itself to the Internet with far fewer IP addresses than there are nodes on its internal network. , is emerging as the key approach). Tables detail FDA-approved validated biomarkers and those in trials to achieve validation.
- Case studies: Genomic Health's Oncotype DX Oncotype DX™, created by Genomic Health, is a diagnostic test that quantifies the likelihood of disease recurrence in women with early-stage breast cancer and assesses the likely benefit from certain types of chemotherapy. and Agendia's Mammaprint.
- Biomarker development environment: recent approvals, reimbursement challenges, supporting consortia.
- Where is the pay-off?: company profiles, revenue trends, industry outlook.
Companies Mentioned:
- Affymetrix
- Agendia
- Biosite
- Cepheid
- Chugai
- Dako
- Eli Lilly Eli Lilly can refer to:
* Eli Lilly and Company, a global pharmaceutical company
* Colonel Eli Lilly (1839-1898), founder of Eli Lilly and Company
* Eli Lilly (industrialist) (1885-1977), former president of Eli Lilly and Company
*
- Exagen Diagnostics
- Fujirebio Diagnostics
- Genentech
- Genomic Health
- Genzyme Genetics
- GlaxoSmithKline
- Immunicon
- Kudos Pharmaceuticals
- LabCorp
- Merck
- Myriad Genetics Myriad Genetics is a leading biopharmaceutical company focused on understanding the relationship between genes, proteins and human diseases in order to develop the next generation of therapeutic and molecular diagnostic products.
- Nanosphere
- Novartis
- Panacea Pharmaceuticals
- Pfizer
- Prometheus Therapeutics & Diagnostics
- OSI Pharmaceuticals
- Roche
- Roche Diagnostics
- Siemens Medical Solutions Siemens Medical Solutions (Siemens Med) is a supplier to the healthcare industry, and is headquartered in Erlangen, Germany. Its U.S. division, Siemens Medical Solutions USA, Inc., is a Delaware corporation, with headquarters in Malvern, Pennsylvania.
- Third Wave Technologies
- Vanda Pharmaceuticals
- Ventana Medical Systems
- Veridex
- VTT VTT Technical Research Centre of Finland
VTT Valtion Teknillinen Tutkimuskeskus (Finnish: Technical Research Centre of Finland)
VTT Vélo Tout Terrain (French: mountain bike; aka ATB or MTB)
- Vysis
- Wyeth
For more information visit http://www.researchandmarkets.com/reports/c86274.
Introduction
Validating a biomarker is a resource-intensive undertaking. Is it worth it? We say, Yes. A biomarker that wins "known validated" status is best positioned for rewards: regulatory approval, optimal reimbursement, incorporation into personalized medicine The external links in this article or section may require cleanup to comply with Wikipedia's content policies. approaches alongside companion therapeutics, partnership and promotion opportunities, and wider awareness and uptake. Companies that recently began fielding biomarker-based tests are reporting success in terms of a revenue upswing. And they have laid the groundwork for validation of tomorrow's biomarker-based tools.
Get the Answers You Need to Shape Your Strategy
In December 2007, Panacea's LC Detect for early lung cancer lung cancer, cancer that originates in the tissues of the lungs. Lung cancer is the leading cause of cancer death in the United States in both men and women. Like other cancers, lung cancer occurs after repeated insults to the genetic material of the cell. diagnosis was named one of Time Magazine's Top 10 Medical Breakthroughs of 2007. What other biomarker-based tests are changing medical practice, and how?
- Validation is a key step in maximizing the clinical and commercial success of a biomarker. What is the validation process? What companies have successfully navigated it? What resources exist to facilitate the process?
- Validated biomarkers are the basis for several marketed companion diagnostics. Which products have received approval? How are these products faring? What tests are in development?
- For companies developing biomarker-based tests, a key strategy that taps the personalized medicine paradigm is to partner with drug developers. Which biomarker companies lead the pack? Which pharmaceutical companies have become involved in personalized medicine and drug/diagnostic co-development?
Scope
- About validated biomarkers: definitions, classifications, the value and process of validation.
- Types of biomarker-based tests: home-brew, de novo [Latin, Anew.] A second time; afresh. A trial or a hearing that is ordered by an appellate court that has reviewed the record of a hearing in a lower court and sent the matter back to the original court for a new trial, as if it had not been previously heard nor decided. , in vitro in vitro /in vi·tro/ (in ve´tro) [L.] within a glass; observable in a test tube; in an artificial environment.
in vi·tro
adj.
In an artificial environment outside a living organism. diagnostic multivariate assay, therapeutic area focus (oncology is a leading area), technology focus (nucleic-acid testing, or NAT (Network Address Translation) An IETF standard that allows an organization to present itself to the Internet with far fewer IP addresses than there are nodes on its internal network. , is emerging as the key approach). Tables detail FDA-approved validated biomarkers and those in trials to achieve validation.
- Case studies: Genomic Health's Oncotype DX Oncotype DX™, created by Genomic Health, is a diagnostic test that quantifies the likelihood of disease recurrence in women with early-stage breast cancer and assesses the likely benefit from certain types of chemotherapy. and Agendia's Mammaprint.
- Biomarker development environment: recent approvals, reimbursement challenges, supporting consortia.
- Where is the pay-off?: company profiles, revenue trends, industry outlook.
Companies Mentioned:
- Affymetrix
- Agendia
- Biosite
- Cepheid
- Chugai
- Dako
- Eli Lilly Eli Lilly can refer to:
* Eli Lilly and Company, a global pharmaceutical company
* Colonel Eli Lilly (1839-1898), founder of Eli Lilly and Company
* Eli Lilly (industrialist) (1885-1977), former president of Eli Lilly and Company
*
- Exagen Diagnostics
- Fujirebio Diagnostics
- Genentech
- Genomic Health
- Genzyme Genetics
- GlaxoSmithKline
- Immunicon
- Kudos Pharmaceuticals
- LabCorp
- Merck
- Myriad Genetics Myriad Genetics is a leading biopharmaceutical company focused on understanding the relationship between genes, proteins and human diseases in order to develop the next generation of therapeutic and molecular diagnostic products.
- Nanosphere
- Novartis
- Panacea Pharmaceuticals
- Pfizer
- Prometheus Therapeutics & Diagnostics
- OSI Pharmaceuticals
- Roche
- Roche Diagnostics
- Siemens Medical Solutions Siemens Medical Solutions (Siemens Med) is a supplier to the healthcare industry, and is headquartered in Erlangen, Germany. Its U.S. division, Siemens Medical Solutions USA, Inc., is a Delaware corporation, with headquarters in Malvern, Pennsylvania.
- Third Wave Technologies
- Vanda Pharmaceuticals
- Ventana Medical Systems
- Veridex
- VTT VTT Technical Research Centre of Finland
VTT Valtion Teknillinen Tutkimuskeskus (Finnish: Technical Research Centre of Finland)
VTT Vélo Tout Terrain (French: mountain bike; aka ATB or MTB)
- Vysis
- Wyeth
For more information visit http://www.researchandmarkets.com/reports/c86274.
Pharmaceutical equipment procurement and validation services offered by Business Biotics Group
Business Biotics Group offers pharmaceutical equipment procurement The fancy word for "purchasing." The procurement department within an organization manages all the major purchases. and validation services for pharmaceutical and biotech bi·o·tech
n. Informal
Biotechnology.
biotech
Noun
short for biotechnology
Noun 1. companies. Business Biotics Group validates the quality of new medical and pharmaceutical equipment in the market through professional monitoring techniques. Business Biotics Group evaluates the medical equipment for pharmaceutical manufacturing and engineering standards. Business Biotics Group provides reliable and cost effective medical equipment procurement and validation services for government hospitals and research institutes. Business Biotics Group uses advanced equipment and strategies for its inspection and validation projects.
Business Biotics Group helps pharmaceutical product manufacturers in launching their new product or equipment to a wider market. With over years of experience in the project management and control industry, Business Biotics Group offers reliable and efficient service to its clients in the medical and pharmaceutical product manufacturing industry.
Business Biotics Group conducts technical analysis and factory acceptance testing (programming) acceptance testing - Formal testing conducted to determine whether a system satisfies its acceptance criteria and thus whether the customer should accept the system.
..... Click the link for more information. procedures for validating the quality of new pharmaceutical equipment or product in the market.
n. Informal
Biotechnology.
biotech
Noun
short for biotechnology
Noun 1. companies. Business Biotics Group validates the quality of new medical and pharmaceutical equipment in the market through professional monitoring techniques. Business Biotics Group evaluates the medical equipment for pharmaceutical manufacturing and engineering standards. Business Biotics Group provides reliable and cost effective medical equipment procurement and validation services for government hospitals and research institutes. Business Biotics Group uses advanced equipment and strategies for its inspection and validation projects.
Business Biotics Group helps pharmaceutical product manufacturers in launching their new product or equipment to a wider market. With over years of experience in the project management and control industry, Business Biotics Group offers reliable and efficient service to its clients in the medical and pharmaceutical product manufacturing industry.
Business Biotics Group conducts technical analysis and factory acceptance testing (programming) acceptance testing - Formal testing conducted to determine whether a system satisfies its acceptance criteria and thus whether the customer should accept the system.
..... Click the link for more information. procedures for validating the quality of new pharmaceutical equipment or product in the market.
Subscribe to:
Posts (Atom)